Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002652 · ClinicalTrials.gov registry record · Phase 2
Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002652 is a Phase 2 study that has completed, run by University of Arkansas.
The verdict
NCT00002652, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients who have refractory or relapsed multiple myeloma or Castleman's disease.
Interventions
- DRUG suramin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1995-05 |
| Est. Completion | 2004-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002652
The ClinicalTrials.gov registry entry for NCT00002652 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which suramin is the first listed.
NCT00002652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002652 about?
NCT00002652 is a clinical study titled "Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients who have refractory or relapsed multiple myeloma or Castleman's disease.
What is the current status of trial NCT00002652?
This trial is currently completed. It is a Phase 2 study. The study started on 1995-05. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00002652?
The interventions under investigation include: suramin (DRUG).
Who is sponsoring clinical trial NCT00002652?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.